- Home
- MAIA vs XLO Comparison
MAIA vs XLO Comparison
Compare MAIA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- XLO
- Stock Information
- Founded
- MAIA 2018
- XLO 2016
- Country
- MAIA United States
- XLO United States
- Employees
- MAIA N/A
- XLO 73
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- XLO Health Care
- Exchange
- MAIA Nasdaq
- XLO Nasdaq
- Market Cap
- MAIA 44.9M
- XLO 43.1M
- IPO Year
- MAIA 2022
- XLO 2021
- Fundamental
- Price
- MAIA $1.11
- XLO $0.81
- Analyst Decision
- MAIA
- XLO Buy
- Analyst Count
- MAIA 0
- XLO 2
- Target Price
- MAIA N/A
- XLO $3.00
- AVG Volume (30 Days)
- MAIA 742.2K
- XLO 811.9K
- Earning Date
- MAIA 11-07-2025
- XLO 11-07-2025
- Dividend Yield
- MAIA N/A
- XLO N/A
- EPS Growth
- MAIA N/A
- XLO N/A
- EPS
- MAIA N/A
- XLO N/A
- Revenue
- MAIA N/A
- XLO $15,001,000.00
- Revenue This Year
- MAIA N/A
- XLO $519.70
- Revenue Next Year
- MAIA N/A
- XLO $44.57
- P/E Ratio
- MAIA N/A
- XLO N/A
- Revenue Growth
- MAIA N/A
- XLO 536.45
- 52 Week Low
- MAIA $1.05
- XLO $0.62
- 52 Week High
- MAIA $3.48
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- MAIA 34.52
- XLO 52.25
- Support Level
- MAIA $1.05
- XLO $0.79
- Resistance Level
- MAIA $1.35
- XLO $0.88
- Average True Range (ATR)
- MAIA 0.10
- XLO 0.06
- MACD
- MAIA -0.03
- XLO 0.00
- Stochastic Oscillator
- MAIA 12.85
- XLO 48.42
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.